Grant: Doctoral: Vanier Canada Graduate Scholarships
University of British Columbia
$150,000.00
Clonal evolution and acquired drug resistance in breast cancer patient xenografts profiled at single cell resolution
FY 2014-15
Summary
Cancer is the leading cause of death in Canada and worldwide. Cancer tumours generally arise from a single cell which has acquired genetic mutations leading to uncontrolled cell division. As cancer cells divide, they acquire additional mutations which are passed down to their descendents. Drug treatment often results in widespread tumour cell death. However, if even a small subset of cells feature mutations which confer treatment resistance, these cells will survive and the cancer will reoccur. While recent discoveries have greatly improved outcomes for cancer patients, the likelihood of survival remains poor following tumour recurrence. This project aims to characterize tumour-cell diversity though computational analysis of data from novel single-cell sequencing experiments in breast cancer models. Together with our collaborators, we will develop and test devices designed to gather data on mutations in individual tumour cells, and create computational models to interpret this data. We will then compare the findings from our model systems with information derived from donated patient tumour samples in order to identify common mutations responsible for drug resistance. This research will lead to a better understanding of breast cancer tumours with drug-resistant tendencies, and permit the development of new tests and targeted treatments to prevent patient relapse. In addition to shedding light on drug resistance in breast cancer, the novel experimental and computational tools developed through this project could later be widely applied to study drug resistance in diverse cancer types.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
318276
Name
Steif Adi
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Clonal evolution and acquired drug resistance in breast cancer patient xenografts profiled at single cell resolution
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Clonal Evolution; Computational Models; Drug Resistance; Single Cell Sequencing; Tumour Heterogeneity
Abstract
Cancer is the leading cause of death in Canada and worldwide. Cancer tumours generally arise from a single cell which has acquired genetic mutations leading to uncontrolled cell division. As cancer cells divide, they acquire additional mutations which are passed down to their descendents. Drug treatment often results in widespread tumour cell death. However, if even a small subset of cells feature mutations which confer treatment resistance, these cells will survive and the cancer will reoccur. While recent discoveries have greatly improved outcomes for cancer patients, the likelihood of survival remains poor following tumour recurrence. This project aims to characterize tumour-cell diversity though computational analysis of data from novel single-cell sequencing experiments in breast cancer models. Together with our collaborators, we will develop and test devices designed to gather data on mutations in individual tumour cells, and create computational models to interpret this data. We will then compare the findings from our model systems with information derived from donated patient tumour samples in order to identify common mutations responsible for drug resistance. This research will lead to a better understanding of breast cancer tumours with drug-resistant tendencies, and permit the development of new tests and targeted treatments to prevent patient relapse. In addition to shedding light on drug resistance in breast cancer, the novel experimental and computational tools developed through this project could later be widely applied to study drug resistance in diverse cancer types.
Competitiondate
201411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Steif, Adi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~